-+ 0.00%
-+ 0.00%
-+ 0.00%

Akeso Announces Phase II/III Trial of Ivonescimab in First-Line Biliary Tract Cancer

PUBT·10/21/2026 12:46:13
Akeso Announces Phase II/III Trial of Ivonescimab in First-Line Biliary Tract Cancer
  • Akeso announced partner Summit Therapeutics' collaboration with ECOG-ACRIN on EA2251, a Phase II/III ivonescimab trial in first-line biliary tract cancer.
  • The study will compare ivonescimab with chemotherapy against pembrolizumab or durvalumab with chemotherapy in patients with advanced disease.
  • Ivonescimab's seventh international registrational trial is its second in biliary tract cancer; US site activations are expected in fourth-quarter 2026.
  • The earlier China-based Phase III HARMONi-GI1 trial showed a clinically meaningful survival benefit for ivonescimab with chemotherapy versus durvalumab with chemotherapy.
  • Detailed HARMONi-GI1 results will be presented at the European Society for Medical Oncology Congress on October 25, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610210842PR_NEWS_USPR_____CN77699) on October 21, 2026, and is solely responsible for the information contained therein.